Search clinical trials for: Dificlir

Total 17 results

Astellas Pharma Global Development, Inc.
Cubist Pharmaceuticals LLC

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

Healthy Subjects | Pharmacokinetics of Fidaxomicin

United States
Optimer Pharmaceuticals LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Clostridium Difficile-associated Diarrhea
Optimer Pharmaceuticals LLC

Completed

Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) (DEFLECT-1)

Clostridium Difficile-Associated Diarrhea (CDAD)
Astellas Pharma S.A.S.

Completed

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE)

Clostridium Difficile Infection

France
Astellas Pharma Europe Ltd.
Merck Sharp & Dohme LLC

Completed

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population (EXTEND)

Clostridium Difficile

Greece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
University of Michigan
Merck Sharp & Dohme LLC

Completed

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

Clostridium Difficile Infection (CDI)

United States
Astellas Pharma Europe B.V.
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) (SUNSHINE)

Clostridium Difficile-associated Diarrhea (CDAD)

United States, Belgium, Italy, Canada, France, Germany, Hungary, Poland, Romania, Spain
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) (PROFILE)

Inflammatory Bowel Disease (IBD) | Clostridium Difficile Infection (CDI)

Austria, France, Greece, Italy, Poland, Russian Federation, United Kingdom
Astellas Pharma Europe B.V.
Cubist Pharmaceuticals LLC

Completed

A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects

Healthy Subjects | Drug-Drug Interaction (DDI) | Intestinal Absorption | Pharmacokinetics of Rosuvastatin | Pharmacokinetics of Fidaxomicin

Germany
Mikrobiomik Healthcare Company S.L.

Completed

Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin

Recurrent Clostridium Difficile Infection | Primary Clostridium Difficile Infection

Spain
Astellas Pharma Europe Ltd.
Cubist Pharmaceuticals LLC

Terminated

A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System (FREEDOM)

Clostridium Difficile

Spain, France, Germany, Greece, Denmark, Austria, Poland
McMaster University

Terminated

Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection

Clostridium Difficile Infection

Canada
Washington University School of Medicine
Centers for Disease Control and Prevention

Withdrawn

Fidaxomicin to Prevent Clostridium Difficile Colonization

Clostridium Difficile Infection

United States
Baylor College of Medicine
Cubist Pharmaceuticals LLC

Terminated

Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury

Spinal Cord Injury | Clostridium Difficile

United States
University of Alberta

Terminated

Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection

Clostridium Difficile

Canada
Optimer Pharmaceuticals LLC

Completed

Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

Diarrhea | Clostridium Infections
Duke University

Completed

Impact of Oral Antibiotic Treatment on C. Difficile (C-Diff)

Diarrhea | Enterocolitis | C. Difficile

United States

3

Subscribe